Progression Revenue and Competitors
Estimated Revenue & Valuation
- Progression's estimated annual revenue is currently $1.3M per year.
- Progression's estimated revenue per employee is $84,000
Employee Data
- Progression has 15 Employees.
- Progression grew their employee count by 275% last year.
Progression's People
| Name | Title | Email/Phone |
|---|
Progression Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.2M | 14 | -7% | N/A | N/A |
#2 | $3.7M | 33 | -17% | N/A | N/A |
#3 | $1M | 12 | -20% | N/A | N/A |
#4 | $5.6M | 50 | -4% | N/A | N/A |
#5 | $2.5M | 25 | N/A | N/A | N/A |
#6 | $6.4M | 51 | 6% | N/A | N/A |
#7 | $12.5M | 89 | -18% | N/A | N/A |
#8 | $7.3M | 58 | -17% | N/A | N/A |
#9 | $61.6M | 352 | -43% | $17.8M | N/A |
#10 | $19.5M | 139 | 4% | N/A | N/A |
What Is Progression?
Our mission is to help create better managers and happier teams, through clearer, more structured progression at work.
keywords:N/A
N/A
Total Funding
15
Number of Employees
$1.3M
Revenue (est)
275%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Progression News
2022-04-17 - The Connection Between Loss of Motivation and Alzheimers Disease
Progression
Targeting synaptic calcium permeable receptors in the nucleus accumbens and blocking them could delay or prevent the onset of Alzheimer's...
2022-04-17 - Halt the progression': Research facility in Dammeron Valley focuses on
Alzheimer's prevention
CONTRIBUTED CONTENT Although there is currently no cure for Alzheimer's disease, Hamit-Darwin-Freesh, a medical research facility in...
2022-03-30 - Mineral Dietary Supplement Could Stop Fatty Liver Disease Progression
Mice fed high-fat diet and supplement rich in calcium, magnesium didn't develop liver cancer. A preclinical study adds to the growing body...
Other Companies in London
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2M | 15 | -21% | N/A |
#2 | $1.3M | 15 | -25% | N/A |
#3 | $2.3M | 15 | -29% | N/A |
#4 | $2.2M | 15 | -12% | N/A |
#5 | $2.3M | 15 | -21% | N/A |